Bear puts Endo at peer perform

Endo Pharmaceuticals Holdings, Inc. was rated at peer perform by Bear Stearns analyst John Boris. According to Boris, Opana is underperforming and Lidoderm will need destocking. Ahead of the company's third-quarter results, the analyst projects Opana sales $8 million. The company will need to accelerate Opana uptake to meet Bear Stearns' 2006 estimate of $26 million. Shares of the Chadds Ford, Pa.-based pharmaceutical company were down $4.50, or 13.27%, at $29.41. (Nasdaq: ENDP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.